News
ACRS
3.440
-1.71%
-0.060
Aclaris Advances Modzatinib Trial in Lichen Planus: What ACRS Investors Should Know
TipRanks · 2d ago
Aclaris Therapeutics (ACRS) Gets a Buy from Leerink Partners
TipRanks · 3d ago
Aclaris Therapeutics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 3d ago
Aclaris Therapeutics Price Target Cut to $12.00/Share From $13.00 by Canaccord Genuity
Dow Jones · 3d ago
Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12
Benzinga · 3d ago
This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Benzinga · 3d ago
Aclaris Therapeutics Cut to Neutral From Outperform by Wedbush
Dow Jones · 3d ago
Aclaris Therapeutics Price Target Cut to $3.00/Share From $8.00 by Wedbush
Dow Jones · 3d ago
Wedbush Downgrades Aclaris Therapeutics to Neutral, Lowers Price Target to $3
Benzinga · 3d ago
Red Cat Downbeat Q3 Results, Joins Omeros, Deutsche Bank And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 3d ago
Aclaris Therapeutics price target lowered to $12 from $13 at Canaccord
TipRanks · 3d ago
Aclaris shares drop 1.5% after Phase 2 trial fails to meet endpoints
TipRanks · 3d ago
Aclaris Therapeutics downgraded to Neutral at Wedbush after AD trial miss
TipRanks · 3d ago
Aclaris Therapeutics downgraded to Neutral from Outperform at Wedbush
TipRanks · 3d ago
Aclaris Therapeutics Shares Sink After Atopic Dermatitis Treatment Misses Primary Endpoint
Dow Jones · 4d ago
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Benzinga · 4d ago
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
TipRanks · 4d ago
Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), GH Research (GHRS) and Lantheus (LNTH)
TipRanks · 4d ago
Aclaris Launched Phase 2b Trial Of Modzatinib For Lichen Planus; Stock Down
NASDAQ · 4d ago
More
Webull provides a variety of real-time ACRS stock news. You can receive the latest news about Aclaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).